Pfizer has developed an RSV Vaccine that can offer adequate protection for newborns and seniors. The information is derived through a series of clinical trials.
Based on the findings of this clinical trial, a significant advisory group for the U.S. Food and Drug Administration last week recommended approval of the Pfizer vaccine for seniors.
The majority of people usually get sniffles from the moderate respiratory virus known as a respiratory syncytial virus (RSV).
Yet, the U.S. Centers for Disease Control and Prevention report that RSV is the most frequent cause of bronchiolitis and pneumonia in children under 1 in the country. Older adults are also in danger from RSV, especially those ill.
Since there is no specific cure, the only option is to treat the symptoms and let the virus do its thing.
To facilitate breathing, doctors may advise oral steroids or an inhaler. Severe cases may require hospitalization. Last year, the nation saw an unusual surge in RSV infections.
“If approved, RSVpreF would help protect infants at their first breath from the devastating effects of this infectious disease, which though well-known, has been particularly evident throughout this RSV season. We look forward to progressing the review of Pfizer’s RSV maternal vaccine candidate with the FDA and other regulatory authorities, given its significant potential to positively contribute to global health in the prevention of RSV in infants,” says a statement from Pfizer.